526 related articles for article (PubMed ID: 14512391)
21. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
22. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
23. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
[TBL] [Abstract][Full Text] [Related]
24. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
25. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
Soignet SL; Frankel SR; Douer D; Tallman MS; Kantarjian H; Calleja E; Stone RM; Kalaycio M; Scheinberg DA; Steinherz P; Sievers EL; Coutré S; Dahlberg S; Ellison R; Warrell RP
J Clin Oncol; 2001 Sep; 19(18):3852-60. PubMed ID: 11559723
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
[TBL] [Abstract][Full Text] [Related]
27. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
28. Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Park JA; Yun JH; Kang HJ; Shin HY; Ahn HS
Pediatr Blood Cancer; 2008 Apr; 50(4):872-4. PubMed ID: 17635008
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Sanz MA; Fenaux P; Lo Coco F;
Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
[TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
31. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
Oberg KC; Bauman JL
Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
[TBL] [Abstract][Full Text] [Related]
32. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW
Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038
[No Abstract] [Full Text] [Related]
33. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Beer TM; Tangen CM; Nichols CR; Margolin KA; Dreicer R; Stephenson WT; Quinn DI; Raghavan D; Crawford ED
Cancer; 2006 Jun; 106(12):2624-9. PubMed ID: 16688776
[TBL] [Abstract][Full Text] [Related]
34. Cardiac toxicity of arsenic trioxide.
Barbey JT
Blood; 2001 Sep; 98(5):1632; author reply 1633-4. PubMed ID: 11547771
[No Abstract] [Full Text] [Related]
35. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide.
Roboz GJ; Ritchie EK; Carlin RF; Samuel M; Gale L; Provenzano-Gober JL; Curcio TJ; Feldman EJ; Kligfield PD
J Clin Oncol; 2014 Nov; 32(33):3723-8. PubMed ID: 25245447
[TBL] [Abstract][Full Text] [Related]
36. Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study.
Mumford JL; Wu K; Xia Y; Kwok R; Yang Z; Foster J; Sanders WE
Environ Health Perspect; 2007 May; 115(5):690-4. PubMed ID: 17520054
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
[TBL] [Abstract][Full Text] [Related]
38. Choline-modulated arsenic trioxide-induced prolongation of cardiac repolarization in Guinea pig.
Sun HL; Chu WF; Dong DL; Liu Y; Bai YL; Wang XH; Zhou J; Yang BF
Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):381-8. PubMed ID: 16623862
[TBL] [Abstract][Full Text] [Related]
39. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
40. Risk/benefit profile of arsenic trioxide.
Rust DM; Soignet SL
Oncologist; 2001; 6 Suppl 2():29-32. PubMed ID: 11331438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
